Clinical trials: Optimized Treatment
CAR T Cell Therapy, CD33 Positive Acute Myelogenous Leukemia
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
Relapsed/refractory acute myeloid leukemia (R/R AML) currently lacks effective CAR-T therapeutic agents due to the absence of tumor-specific target antigens.
- Trial name
- NCT07538713
- Testing
- Functionally optimized CD33 CAR-T
- Volunteers
- 18 people
- Sponsor
- Qi deng
Coronary Artery Disease, Chest Syndrome
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine…
- Conditions
- Coronary Artery Disease, Chest Syndrome, Acute Myocardial Infarction, Heart Failure
- Trial name
- DYNAMITE (NCT04709900)
- Testing
- CT angiography, FFR-CT and stress CT myocardial perfusion
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
B-Cell Malignancies
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
This study is to determine the safety, including potential dose limiting toxicities, and efficiency of ET019002-T cells and the duration of in vivo survival of ET019002-T cells in patients with relapsed/refractory B-Cell…
- Trial name
- NCT03642496
- Testing
- Low dose ET019002- T Cells, Middle dose ET019002- T Cells, High dose ET019002- T Cells
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Multidrug Resistant Tuberculosis, Pediatric
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
The purpose of this trial is to determine the pediatric dose of delamanid that is equivalent to the adult dose already shown to be effective against multidrug-resistant tuberculosis.
- Trial name
- NCT01856634
- Testing
- 100 mg Delamanid, 50 mg Delamanid, 25 mg Pediatric Formulation Delamanid
- Where
- 2 sites in Philippines, South Africa
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
HIV Infections
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to <6 years of age.
- Trial name
- PRINCE1 (NCT01099579)
- Testing
- Atazanavir powder, Ritonavir oral solution, Atazanavir capsules
- Where
- 18 sites in Brazil, Chile and 4 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
HIV, Pediatric
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and…
- Trial name
- NCT01691794
- Testing
- Atazanavir, Ritonavir
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Liver Fibrosis
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients.
- Trial name
- HBV (NCT03920605)
- Testing
- Tenofovir Disoproxil Fumarate, Peginterferon Alfa-2a, Peginterferon Alfa-2b
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Australia Antigen Positive, Hepatitis B
Optimization of Antiviral Therapy of Chronic HBV Infection
Along with the improvement of the accuracy of detection of HBV serological markers, the optimization of antiviral therapy for patients with chronic hepatitis B (CHB) infection becomes feasible.
- Conditions
- Australia Antigen Positive, Hepatitis B, Adverse Effects
- Trial name
- NCT01623778
- Testing
- Interferon Alfa-2a add on ADV
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Changhai Hospital
HIV Infections, Human Immunodeficiency Virus
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
The study will compare the safety and efficacy of an investigation nucleoside analog reverse transcriptase inhibitor (NRTI), dexelvucitabine (DFC), to an approved NRTI, lamivudine (3TC) in HIV treatment-experienced patients who…
- Trial name
- DECLARE (NCT00300573)
- Testing
- Dexelvucitabine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
HIV Infections
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes).
- Trial name
- MOTIVATE 1 (NCT00098306)
- Testing
- Maraviroc (UK-427,857), Optimized Background Therapy
- Where
- 22 sites in United States, Canada
- Volunteers
- 601 people
- Sponsor
- ViiV Healthcare
Pyruvate Kinase Deficiency
Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
This is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).
- Trial name
- NCT06422351
- Testing
- RP-L301
- Where
- 3 sites in United States, Spain
- Volunteers
- 10 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Spasticity, Muscle, Microcephaly
Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss.
- Conditions
- Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation
- Trial name
- NCT05518188
- Testing
- MELPIDA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Elpida Therapeutics SPC
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia
- Trial name
- NCT02159495
- Testing
- cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
HIV-1-infection
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
The goal of this clinical study is to learn more about the study drug, lenacapavir (LEN). The study will assess the safety, tolerability, and efficacy of long-acting LEN when combined with other medicines in adolescents and…
- Trial name
- NCT06749054
- Testing
- Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen (OBR)
- Where
- 9 sites in United States, South Africa
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Leukemia, Infection
Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias
Hepatic candidiasis is a frequent complication in patients receiving intensive chemotherapy for acute leukemia. Hepatic lesions may be detected by computerized tomographic (CT) scans, but there is no standardized CT protocol for…
- Trial name
- NCT01207843
- Testing
- Imaging
- Where
- Switzerland
- Volunteers
- 88 people
- Sponsor
- University of Zurich
Antibody-drug Conjugates, HER2-low Breast Cancer
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs).
- Conditions
- Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
- Trial name
- NCT06877416
- Testing
- Non-intervention research
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus
Adjunctive Metformin Therapy in Double Diabetes
The significance of this project is to investigate the effects of adjunctive metformin therapy in children and adolescents with double diabetes.
- Trial name
- AMTIDD (NCT01334125)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Massachusetts, Worcester
HIV
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients…
- Trial name
- PRINCE2 (NCT01335698)
- Testing
- Atazanavir Sulphate, Ritonavir
- Where
- 32 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple…
- Trial name
- NCT00377065
- Testing
- raltegravir
- Sponsor
- Merck Sharp & Dohme LLC
Tourette Syndrome, Tics
Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback
The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults. Hypotheses: 1.
- Conditions
- Tourette Syndrome, Tics, Tourette Syndrome in Adolescence
- Trial name
- CoBRa (NCT06873841)
- Testing
- Cognitive psychophysiological, Cognitive psychophysiological and Biofeedback
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Université du Québec a Montréal